Fig 1: GPRC5A modulates the Hippo pathway by mediating YAP1 transcription. A–D The correlation between GPRC5A and CYR61, cyclin D1, c-Myc and CTGF in pancreatic cancer was evaluated using the GEPIA database. E, F Western blotting analysis of MST1/2, p-MST1/2, LATS1/2, p-LATS1/2, YAP1, p-YAP1, CYR61, cyclin D1, c-Myc and CTGF expression after GPRC5A downregulation. Student’s t test, *p < 0.05, **p < 0.01, ***p < 0.001. G The ratio between YAP1 and p-YAP1 after downregulation of GPRC5A. H RT-PCR analysis of YAP1, CYR61, cyclin D1, c-Myc and CTGF after downregulation of GPRC5A. Student’s t test, *p < 0.05, **p < 0.01, ***p < 0.001. I-J Western blotting analysis of MST1/2, p-MST1/2, LATS1/2, p-LATS1/2, YAP1, p-YAP1, CYR61, cyclin D1, c-Myc and CTGF expression after GPRC5A upregulation. Student’s t test, *p < 0.05, **p < 0.01, ***p < 0.001. K The ratio between YAP1 and p-YAP1 after upregulation of GPRC5A. L RT-PCR analysis of YAP1, CYR61, cyclin D1, c-Myc and CTGF after upregulation of GPRC5A. Student’s t test, *p < 0.05, **p < 0.01, ***p < 0.001